A Phase 2, Randomized, Biomarker-Driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels of MCL-1 Dependence
You are being asked to take part in this study because you have acute myeloid leukemia (AML) that is either relapsed (has returned) or refractory (has not responded to treatment) or you have been newly diagnosed with high-risk (NDHR) AML. Additionally, you had pre-screening tests that showed that you expressed enough of a certain protein called MCL-1 to be considered to be eligible to take part in this study. The goal of this clinical research study is to learn if adding alvocidib to the combination of cytarabine and mitoxantrone can help to control AML. The safety of the study drug combinations will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 05/16/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: